William Blair Decreases Earnings Estimates for Neuronetics

Neuronetics, Inc. (NASDAQ:STIM) – Research analysts at William Blair decreased their FY2024 earnings per share estimates for shares of Neuronetics in a research report issued on Tuesday, November 12th. William Blair analyst M. Andrew now expects that the company will earn ($1.16) per share for the year, down from their previous estimate of ($0.83). William Blair has a “Market Perform” rating on the stock. The consensus estimate for Neuronetics’ current full-year earnings is ($0.87) per share. William Blair also issued estimates for Neuronetics’ Q4 2024 earnings at ($0.28) EPS, Q1 2025 earnings at ($0.25) EPS, Q2 2025 earnings at ($0.22) EPS, Q3 2025 earnings at ($0.21) EPS, Q4 2025 earnings at ($0.15) EPS and FY2025 earnings at ($0.84) EPS.

STIM has been the subject of several other research reports. Canaccord Genuity Group lowered their price objective on shares of Neuronetics from $6.00 to $3.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. JMP Securities decreased their target price on shares of Neuronetics from $7.00 to $3.00 and set a “market outperform” rating for the company in a research note on Wednesday, August 14th.

Neuronetics Stock Down 10.1 %

Shares of Neuronetics stock opened at $0.71 on Friday. Neuronetics has a 12 month low of $0.52 and a 12 month high of $5.07. The company has a quick ratio of 2.37, a current ratio of 3.16 and a debt-to-equity ratio of 4.90. The stock has a market cap of $21.52 million, a PE ratio of -0.58 and a beta of 2.21. The business has a fifty day simple moving average of $0.90 and a 200 day simple moving average of $1.51.

Insider Transactions at Neuronetics

In related news, Director Robert Cascella acquired 100,000 shares of the stock in a transaction on Thursday, September 12th. The shares were purchased at an average price of $0.75 per share, for a total transaction of $75,000.00. Following the purchase, the director now directly owns 453,098 shares in the company, valued at approximately $339,823.50. The trade was a 28.32 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Over the last ninety days, insiders have acquired 141,776 shares of company stock valued at $110,420. 9.80% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Neuronetics

A number of institutional investors have recently modified their holdings of the business. SG Americas Securities LLC acquired a new position in Neuronetics during the first quarter worth about $62,000. Dorsey & Whitney Trust CO LLC boosted its position in Neuronetics by 53.0% in the first quarter. Dorsey & Whitney Trust CO LLC now owns 48,652 shares of the company’s stock valued at $232,000 after buying an additional 16,855 shares in the last quarter. Silvercrest Asset Management Group LLC grew its stake in shares of Neuronetics by 4.6% during the first quarter. Silvercrest Asset Management Group LLC now owns 1,178,365 shares of the company’s stock worth $5,609,000 after buying an additional 51,881 shares during the last quarter. FourWorld Capital Management LLC bought a new stake in shares of Neuronetics during the first quarter worth $171,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of Neuronetics by 63.0% during the second quarter. Assenagon Asset Management S.A. now owns 135,746 shares of the company’s stock worth $244,000 after buying an additional 52,450 shares in the last quarter. Institutional investors and hedge funds own 53.59% of the company’s stock.

About Neuronetics

Neuronetics, Inc, a commercial stage medical technology company, designs, develops, and markets products for patients with neurohealth disorders in the United States and internationally. The company offers NeuroStar Advanced Therapy System, a non-invasive and non-systemic office-based treatment to treat adult patients with major depressive disorder.